Regeneron Pharmaceuticals just scooped up 23andMe and its treasure trove of 15 million customer DNA profiles for a bargain basement $256 million – which works out to roughly $2.56 per genetic ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

Through the deal, Regeneron aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its popular ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron to buy bankrupt DNA testing firm ...

Regeneron is now poised to step in and purchase this customer data, for $256 million.The sale includes 23andMe’s customer-facing genomics service arm, as well as its health and research arm.

Regeneron said Monday it will "prioritize the privacy, security and ethical use" of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe ...

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on the deal's impact looms.

The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including al ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Posted 2025-05-19T12:22:14+00:00 - Updated 2025 ...

From Reuters Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said ...